Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial

American Heart Journal

Volumn 151, Issue 5, 2006, Pages 992-998

  McMurray, John J V ^a   Young, James B ^b   Dunlap, Mark E ^c   Granger, Christopher B ^d   Hainer, James ^e   Michelson, Eric L ^e   Earle, Steven ^e   Olofsson, Bertil ^f   Östergren, Jan ^g   Yusuf, Salim ^h   Swedberg, Karl ⁱ   Pfeffer, Marc A ^j  

^a WESTERN INFIRMARY   (United Kingdom)

^b LERNER RESEARCH INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e ASTRAZENECA   (United Kingdom)

^f ASTRAZENECA R AND D   (Sweden)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h Ontario Canada   (Canada)

ⁱ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIGITALIS GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; LISINOPRIL; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; TRANDOLAPRIL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HAZARD; HEART DEATH; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 33646094699     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.06.038     Document Type: Article

References (12)

1. Carson P.E. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure. Am Heart J 140 (2000) 361-366
2. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
3. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987) 1429-1435
4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
5. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 (1991) 303-310
6. Packer M., Califf R.M., Konstam M.A., et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106 (2002) 920-926
7. Remme W.J., Riegger G., Hildebrandt P., et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther 18 (2004) 57-66
8. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
9. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283 (2000) 1295-1302
10. http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-409251-03-AstraZeneca-Dosing.ppt.
11. Nanas J.N., Alexopoulos G., Anastasiou-Nana M.I., et al. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group. J Am Coll Cardiol 36 (2000) 2090-2095
12. Remme W.J., Swedberg K., and Task force for the diagnosis and treatment of chronic heart failure. European Society of Cardiology guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22 (2001) 1527-1560